Markus Meyer, MD
Cardiovascular Disease · Minneapolis, MNNPI 1003871955
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $743,501 of the $786,217 with a category attached, or 94.6%. Medtronic accounts for 100.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $274,221, 2.1 times the $130,506 reported in 2019. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $8453.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$786K
- Boston Scientific$107
- AstraZeneca$26
- Biotronik Inc.$13
Across 58 payments — averaging $6319.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$367K
What the payments were for
- Royalty or licence$743,50195%
- Consulting fees$12,8352%
- Speaking & faculty fees$18,9202%
- Travel & lodging$7,2811%
- Food & beverage$3,6800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 90 | $786,070 |
| Boston Scientific | 1 | $107 |
| AstraZeneca | 1 | $26 |
| Biotronik Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,522
- AZURE XT DR MRI SURESCAN$121
- Adapta$108
- EMPOWER Leadless Pacemaker System_CRM$107
How this compares
$786,217 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $54,362 |
| EliquisApixaban | 17 | $19,121 |
| Atorvastatin Calcium | 89 | $1,432 |
| Losartan Potassium | 73 | $1,140 |
| Spironolactone | 107 | $1,136 |
| Chlorthalidone | 41 | $941 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $788 |
| Cilostazol | 20 | $570 |
| Furosemide | 40 | $471 |
| Amlodipine Besylate | 38 | $447 |
| Valsartan | 12 | $399 |
| Torsemide | 15 | $382 |
| Rosuvastatin Calcium | 21 | $296 |
| Potassium Chloride | 14 | $287 |
| Lisinopril | 11 | $140 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
- Tamas AlexyMinneapolis$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.